News

Novo Nordisk's Moat Is Deeper Than You Think
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
2 Beaten-Down Dividend Growth Stocks to Buy on the Dip
It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high. Shares of Novo Nordisk and ...